The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Ali Tehrani Biography and Net Worth

CEO of Zymeworks

Dr. Tehrani is one of our co-founders and has served as our President and Chief Executive Officer and as a member of our Board of Directors since the Company’s inception in September 2003. He has been an integral part of many of our corporate achievements including raising seed and angel financing and overseeing our technical operations and patent filings. Dr. Tehrani holds both Bachelor’s and Master’s of Science degrees in Biochemistry from the University of Massachusetts, and has a Doctoral degree in Microbiology and Immunology from the University of British Columbia. While completing his Ph.D. degree he co-founded the Student Biotechnology Network, for which he received the UBC Faculty of Science Achievement Award for Outstanding Leadership in 2002. Dr. Tehrani is a member of the board of directors at Creatus Biosciences Inc. and BIOTECanada and has served as a board director for the Student Biotechnology Network, CQDM, LifeSciences British Columbia, and on the MITACS Industrial Advisory Board. He was also a member of British Columbia’s Premier’s Technology Council from 2016 to 2018.

What is Ali Tehrani's net worth?: The estimated net worth of Ali Tehrani is at least $4.06 million as of July 15th, 2021. Dr. Tehrani owns 264,125 shares of Zymeworks stock worth more than $4,064,884 as of November 15th. This net worth approximation does not reflect any other assets that Dr. Tehrani may own. Learn More about Ali Tehrani's net worth.
How do I contact Ali Tehrani?: The corporate mailing address for Dr. Tehrani and other Zymeworks executives is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. Zymeworks can also be reached via phone at (302) 274-8744 and via email at [email protected]. Learn More on Ali Tehrani's contact information.
Has Ali Tehrani been buying or selling shares of Zymeworks?: Ali Tehrani has not been actively trading shares of Zymeworks within the last three months. Most recently, Ali Tehrani sold 3,800 shares of the business's stock in a transaction on Thursday, July 15th. The shares were sold at an average price of $36.00, for a transaction totalling $136,800.00. Following the completion of the sale, the chief executive officer now directly owns 264,125 shares of the company's stock, valued at $9,508,500. Learn More on Ali Tehrani's trading history.
Who are Zymeworks' active insiders?: Zymeworks' insider roster includes Neil Josephson (Insider), Neil Klompas (CFO), Kathryn O'Driscoll (Insider), James Priour (Insider), and Ali Tehrani (CEO). Learn More on Zymeworks' active insiders.
Are insiders buying or selling shares of Zymeworks?: During the last twelve months, insiders at the sold shares 7 times. They sold a total of 40,583 shares worth more than $436,263.55. The most recent insider tranaction occured on January, 8th when CFO Christopher Astle sold 1,431 shares worth more than $16,055.82. Insiders at Zymeworks own 1.9% of the company. Learn More about insider trades at Zymeworks.
Information on this page was last updated on 1/8/2024.

Ali Tehrani Insider Trading History at Zymeworks

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/15/2021	Sell	3,800	$36.00	$136,800.00	264,125
7/12/2021	Sell	12,669	$36.12	$457,604.28	272,994
3/10/2021	Sell	4,392	$34.95	$153,500.40	264,717
12/7/2020	Sell	850	$56.16	$47,736.00	257,009
11/2/2020	Sell	3,500	$39.04	$136,640.00	257,009
4/3/2020	Buy	575	$33.39	$19,199.25	256,009
3/29/2019	Sell	3,000	$16.24	$48,720.00

Ali Tehrani Buying and Selling Activity at Zymeworks

Zymeworks Company Overview

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Today's Range

Now: $15.39

$15.00

$16.24

50 Day Range

MA: $13.51

$11.70

$17.40

2 Week Range

Now: $15.39

$7.54

$17.70

Volume

627,915 shs

Average Volume

625,659 shs

Market Capitalization

$1.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16

Financial Prophecy

From Porter & Company | Ad